Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

1 DEFINITY ® (Package Insert), North Billerica, MA, Lantheus Medical Imaging, Inc., 2017. 2 Parker JM, et al, Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.
Nasdaq

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Medscape

FDA approves new ultrasound contrast agent

Wilmington, DE -DuPont Pharmaceuticals announced today they have received FDA approval for their Definity? (Perflutren Lipid Microsphere) ultrasound contrast agent. Definity is used to improve the ...